Lakewood-Amedex Biotherapeutics annual shares outstanding
2023
2024
2025
Lakewood-Amedex Biotherapeutics Shares Outstanding History (LABT)
Lakewood-Amedex Biotherapeutics reported 699,648 shares outstanding at the end of fiscal 2025.
View full Lakewood-Amedex Biotherapeutics company overviewLakewood-Amedex Biotherapeutics annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 699,648 | −693,916 | −49.79% |
| 2024 | 2024-12-31 | 1.4M | 0 | 0.00% |
| 2023 | 2023-12-31 | 1.4M | — | — |
Lakewood-Amedex Biotherapeutics quarterly shares outstanding
Q4.24
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 2.2M | — | — |
| Q1 2026 | 2026-03-31 | 704,333 | — | — |
| Q4 2025 | 2025-12-31 | 699,648 | −693,916 | −49.79% |
| Q3 2025 | 2025-09-30 | 1.4M | — | — |
| Q4 2024 | 2024-12-31 | 1.4M | — | — |
Lakewood-Amedex Biotherapeutics Share Buyback History
A share buyback, also called a stock repurchase, is when a company uses cash to buy its own shares. Lakewood-Amedex Biotherapeutics share buyback history shows the reported cash used for repurchases. Buybacks can reduce shares outstanding, but issuance, stock-based compensation, acquisitions, and stock splits can change the share count separately.
Lakewood-Amedex Biotherapeutics used $50,000 to repurchase common stock in fy 2025. Across the latest 3 reported fiscal years, total share repurchases were $1.6M. The latest reported quarter showed $0 of share repurchases.
| Fiscal year | Period ended | Share repurchases |
|---|---|---|
| 2025 | 2025-12-31 | $50,000 |
| 2024 | 2024-12-31 | $1.5M |
| 2023 | 2023-12-31 | $0 |
TickerStat uses SEC-reported cash payments for common-stock repurchases. The amounts describe capital returned through buybacks; they are not a forecast or a measure of the number of shares retired.
Lakewood-Amedex Biotherapeutics shares outstanding trends
Between the periods ended 2023-12-31 and 2025-12-31, Lakewood-Amedex Biotherapeutics's shares outstanding moved from 1.4M to 699,648, a change of −693,916. The latest reported quarter, Q2 2026, shows 2.2M.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when a stock-split conversion ratio is reported directly or evidenced by a later filing’s restated historical share balance. After repeated reverse splits, an old period can represent less than one current-basis share; this is a split-adjusted equivalent, not a literal historical certificate count. Values remain as reported when no reliable split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Lakewood-Amedex Biotherapeutics source filings ↗